[go: up one dir, main page]

MX2019002999A - Formulaciones de analogo de prostaciclina. - Google Patents

Formulaciones de analogo de prostaciclina.

Info

Publication number
MX2019002999A
MX2019002999A MX2019002999A MX2019002999A MX2019002999A MX 2019002999 A MX2019002999 A MX 2019002999A MX 2019002999 A MX2019002999 A MX 2019002999A MX 2019002999 A MX2019002999 A MX 2019002999A MX 2019002999 A MX2019002999 A MX 2019002999A
Authority
MX
Mexico
Prior art keywords
formulations
compositions
preformulation
pah
analog
Prior art date
Application number
MX2019002999A
Other languages
English (en)
Other versions
MX390136B (es
Inventor
Tiberg Fredrik
Nistor Catalin
Johnsson Markus
Barauskas Justas
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615754.7A external-priority patent/GB201615754D0/en
Priority claimed from GBGB1621277.1A external-priority patent/GB201621277D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2019002999A publication Critical patent/MX2019002999A/es
Publication of MX390136B publication Critical patent/MX390136B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención hace referencia a una preformulación inyectable que comprende: a) al menos uno de un monoacil, diacil o triacil lípido y/o un tocoferol; b) opcionalmente, al menos un fosfolípido; c) al menos un solvente orgánico biocompatible y d) al menos un análogo de prostaciclina o una sal de este; en donde la preformulación forma, o es capaz de formar, al menos una estructura de fase cristalina líquida tras el contacto con un fluido acuoso en exceso. Adicionalmente, las composiciones pueden comprender cosolventes polares. Se proveen métodos de tratamiento, particularmente, para la gestión de hipertensión arterial pulmonar (PAH), PAH grave, enfermedad de Raynaud, isquemia y afecciones relacionadas, así como usos correspondientes de las composiciones. También se proveen dispositivos de administración que comprenden las formulaciones y kits que comprenden los dispositivos.
MX2019002999A 2016-09-15 2017-09-15 Formulaciones de analogo de prostaciclina. MX390136B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615754.7A GB201615754D0 (en) 2016-09-15 2016-09-15 Formulations
GBGB1621277.1A GB201621277D0 (en) 2016-12-14 2016-12-14 Formulations
PCT/EP2017/073359 WO2018050864A1 (en) 2016-09-15 2017-09-15 Prostacyclin analogue formulations

Publications (2)

Publication Number Publication Date
MX2019002999A true MX2019002999A (es) 2019-07-18
MX390136B MX390136B (es) 2025-03-20

Family

ID=59887281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002999A MX390136B (es) 2016-09-15 2017-09-15 Formulaciones de analogo de prostaciclina.

Country Status (17)

Country Link
US (3) US11369617B2 (es)
EP (1) EP3512495B1 (es)
JP (1) JP7527785B2 (es)
KR (1) KR20190083645A (es)
CN (1) CN109715138B (es)
AU (1) AU2017328630B2 (es)
CA (1) CA3036307A1 (es)
DK (1) DK3512495T3 (es)
ES (1) ES2933175T3 (es)
IL (1) IL265270B (es)
LT (1) LT3512495T (es)
MX (1) MX390136B (es)
PL (1) PL3512495T3 (es)
PT (1) PT3512495T (es)
RU (1) RU2757903C2 (es)
SI (1) SI3512495T1 (es)
WO (1) WO2018050864A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109150387B (zh) 2017-06-16 2023-04-28 华为技术有限公司 发送参考信号的方法、接收参考信号的方法和通信装置
WO2020240018A1 (en) 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
MX2022016437A (es) * 2020-06-30 2023-01-30 Chong Kun Dang Pharmaceutical Corp Composicion inyectable que comprende un analogo de gnrh.
WO2022067336A1 (en) * 2020-09-25 2022-03-31 Algorithm Sciences, Inc. Compositions and methods for vasodilator delivery
WO2024107096A1 (en) * 2022-11-14 2024-05-23 Camurus Ab Treprostinil formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125255A1 (de) 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
ES2152324T3 (es) 1993-07-28 2001-02-01 Pharmaderm Lab Ltd Vesiculas lipidicas multilaminares bifasicas.
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7417070B2 (en) * 2003-05-22 2008-08-26 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
KR20070054644A (ko) * 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 미립자 제형으로 흡입된 일로프로스트에 의한 폐고혈압의치료
EP1845942B1 (en) 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
TWI624271B (zh) 2011-05-25 2018-05-21 凱慕路斯公司 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途
EP2741738A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2741781A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
WO2013038460A1 (ja) 2011-09-16 2013-03-21 株式会社日立製作所 画像表示システム及びその方法
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
EP3326613A1 (en) * 2012-07-26 2018-05-30 Camurus AB Opioid formulations
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Also Published As

Publication number Publication date
AU2017328630B2 (en) 2020-06-18
CN109715138A (zh) 2019-05-03
JP2019529408A (ja) 2019-10-17
MX390136B (es) 2025-03-20
IL265270B (en) 2022-09-01
EP3512495A1 (en) 2019-07-24
US20250319097A1 (en) 2025-10-16
IL265270A (en) 2019-05-30
US20190255068A1 (en) 2019-08-22
DK3512495T3 (da) 2022-12-05
RU2019108832A (ru) 2020-10-15
KR20190083645A (ko) 2019-07-12
RU2757903C2 (ru) 2021-10-22
ES2933175T3 (es) 2023-02-02
CN109715138B (zh) 2022-06-28
RU2019108832A3 (es) 2020-11-30
US11369617B2 (en) 2022-06-28
PT3512495T (pt) 2023-02-15
US20220387445A1 (en) 2022-12-08
SI3512495T1 (sl) 2023-01-31
LT3512495T (lt) 2022-12-27
JP7527785B2 (ja) 2024-08-05
CA3036307A1 (en) 2018-03-22
EP3512495B1 (en) 2022-11-09
PL3512495T3 (pl) 2023-01-23
WO2018050864A1 (en) 2018-03-22
AU2017328630A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX2019002999A (es) Formulaciones de analogo de prostaciclina.
AR106049A1 (es) Formulaciones de liberación controlada
CU20130158A7 (es) Formulaciones peptidicas de liberación controlada
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY35293A (es) Isotiazoles sustituidos con amino
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR087556A1 (es) Composicion que contiene principio activo, aceite y liquido ionico
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
PE20161239A1 (es) Compuesto de ciclopenteno y ciclopentadieno para controlar plagas de invertebrados
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.